References
- Saudi Arabia: the latest coronavirus counts, charts and maps. Reuters, 2021, Accessed 2021 Apr 11. Available from: https://graphics.reuters.com/world-coronavirus-tracker-and-maps/countries-and-territories/saudi-arabia/
- Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 vaccine (Chadox1-S [Recombinant]) – COVID-19 vaccine astrazeneca (other viral vaccines). Ema.Europa.Eu, 2021, cited 2021 Apr 11. Available from: https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant-covid_en.pdf
- World Health Organization. Causality assessment of an adverse event following immunization (AEFI). In: User manual for the revised WHO Classification. Second ed. Geneva, Switzerland: WHO; 2018.
- Capecchi M, Abbattista M, Martinelli I. Cerebral venous sinus thrombosis. J Thromb Haemost. 2018 Oct;16(10):1918–1931. Epub 2018 Jul 11. PMID: 29923367…
- Coutinho JM, Zuurbier SM, Aramideh M, et al. The incidence of cerebral venous thrombosis: a cross-sectional study. Stroke. 2012 Dec;43(12):3375–3377. Epub 2012 Sep 20. PMID: 22996960.
- Devasagayam S, Wyatt B, Leyden J, et al. Cerebral venous sinus thrombosis incidence is higher than previously thought: a retrospective population-based study. Stroke. 2016 Sep;47(9):2180–2182. Epub 2016 Jul 19. PMID: 27435401.
- Algahtani HA, Abdu AP, Shami AM, et al. Cerebral venous sinus thrombosis in Saudi Arabia. Neurosciences (Riyadh). 2011 Oct;16(4):329–334. PMID: 21983375.
- Kajtazi NI, Zimmerman VA, Arulneyam JC, et al. Cerebral venous thrombosis in Saudi Arabia. Clinical variables, response to treatment, and outcome. Neurosciences (Riyadh). 2009 Oct;14(4):349–354. PMID: 21048649.
- Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021 Apr 9. Epub ahead of print. PMID: 33835769. DOI:https://doi.org/10.1056/NEJMoa2104840
- Graf T, Thiele T, Klingebiel R, et al. Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. J Neurol. 2021 May 22:1–3 Epub ahead of print. PMID: 34023956; PMCID: PMC8140563. DOI:https://doi.org/10.1007/s00415-021-10599-2.
- Astrazeneca’S COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low platelets - European Medicines Agency. European Medicines Agency, 2021. cited 2021 Apr 10. Available from: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood
- Astrazeneca’S COVID-19 Vaccine. Spa.Gov.Sa, 2021. cited 2021 Apr 20. Available from: https://www.spa.gov.sa/viewstory.php?lang=ar&newsid=2219569
- Kelland K, Guarascio F. Italy, Britain suggest age limits for astrazeneca vaccine but still recommend It. U.S., 2021. cited 2021 Apr 14. Available from: https://www.reuters.com/article/health-coronavirus-astrazeneca-idUSKBN2BU1R0
- Guidance produced from the expert haematology panel (EHP) focussed on syndrome of thrombosis and thrombocytopenia occurring after coronavirus vaccination. B-S-H.Org.Uk, 2021. cited 2021 Apr 11. Available from: https://b-s-h.org.uk/media/19512/guidance-version-10-on-mngmt-of-thrombosis-with-thrombocytopenia-occurring-after-c-19-vaccine_20210401.pdf
- Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021 Apr 27;S1473-3099(21):00224. Epub ahead of print. PMID: 33930320; PMCID: PMC8078878.
- Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021 May 13;373:n1088